Is geographic atrophy a rare disease?
More than 5 million people worldwide have geographic atrophy, 2 including nearly 1 million people in the U.S. In developed nations, approximately 1 in 29 people over age 75 have geographic atrophy, 3,4,5 which increases to nearly 1 in 4 people over age 90.
Can geographic atrophy be treated?
Recent findings: There are currently no treatments for GA, a form of advanced AMD that causes significant visual morbidity. Currently, therapeutic candidates are being developed to delay further progression of GA or even attempt to reverse some of the damage.
What is the cause of geographic atrophy?
The most pronounced risk factor is increasing age and family history of AMD. Smoking history increases the risk of GA significantly. Both active smokers, but also former smokers are at greater risk of developing geographic atrophy.
How quickly does geographic atrophy progress?
Overall, GA progression rates reported in the literature for total study populations range from 0.53 to 2.6 mm2/year (median, ∼1.78 mm2/year), assessed primarily by color fundus photography or fundus autofluorescence (FAF) imaging.
Is geographic atrophy the same as macular degeneration?
Geographic atrophy (GA), is an advanced form of age-related macular degeneration (AMD), affecting the retina, a part of the eye that sends information to the brain to enable sight.
Is geographic atrophy the same as dry AMD?
Geographic atrophy (GA) is considered the late stage of the dry form of age-related macular degeneration (AMD)(1). GA is less common than neovascular AMD and it is responsible for 10-20% of cases of legal blindness in this condition(2,3,4), affecting more than 5 million people wordwilde(5).
What are the symptoms of geographic atrophy?
Symptoms of Geographic Atrophy
- Difficulty reading in dim lighting situations.
- Central vision loss.
- Black spot in central vision.
- Slower reading speed.
- Glare.
- No change in peripheral vision.
What is the difference between geographic atrophy and dry AMD?
What does geographic atrophy look like?
Upon examination by an ophthalmologist or retina specialist, these areas of atrophy often look like a map which led to the term “geographic atrophy.” GA leads to central scotomas, which are blind or blurry spots in the central field of vision.
Is there a treatment for dry macular degeneration?
As of now, there’s no treatment for dry macular degeneration. However, there are many clinical trials in progress. If your condition is diagnosed early, you can take steps to help slow its progression, such as taking vitamin supplements, eating healthfully and not smoking.
What does geographic atrophy look like on OCT?
SD-OCT scans of geographic atrophy, reveals RPE thinning, loss of EPIS and COST lines, depression of the inner retinal layers as the outer layers are loss, and increase visibility of Bruch’s membrane and the choroid.
What is the newest treatment for macular degeneration?
The Food and Drug Administration (FDA) has approved a new drug for treating two conditions that cause vision loss. The drug Vabysmo (faricimab-svoa) treats wet age-related macular degeneration (AMD) and diabetic macular edema (DME), two of the leading causes of vision loss.
What is geographic atrophy (GA)?
Geographic atrophy (GA) is an advanced stage of age-related macular degeneration (AMD) that results in continuous progressive degeneration of macula. This condition is marked by widespread atrophy of the retinal pigment epithelium, choriocapillaris, and outer retinal tissue.
What is the forecast period of geographic atrophy market research report?
According to a Comprehensive Research Report by Market Research Future (MRFR), “ Geographic Atrophy Market information by Age Group, Diagnosis, Therapeutic Agents Clinical Phase End-User, and Region – Forecast till 2027 ”, the market is expanding at a 7.5% CAGR by 2027.
Why Genentech for R&D?
Rigorous and groundbreaking science has always been at the core of what we do at Genentech. Our R&D activities are focused on applying excellent science to discover and develop potential new medicines with the goal of becoming first-in-class or best-in-class therapeutics.